<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070975</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0634</org_study_id>
    <nct_id>NCT05070975</nct_id>
  </id_info>
  <brief_title>Severity of RSV Infections in Twins</brief_title>
  <acronym>TwinSeVeRS</acronym>
  <official_title>Phenotype Severity of RSV-infections in Twins During the First Year of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory syncytial virus (RSV) infection is the most common cause of severe lower&#xD;
      respiratory tract infection (LRTI) in the pediatric population worldwide. Age at the time of&#xD;
      infection, prematurity, multiparity, exposure to smoke and the level of passive immunity&#xD;
      transmitted at birth are the main risk factors for lower respiratory infection associated&#xD;
      with RSV. Other factors, including the innate immune response, respiratory microbiota, and&#xD;
      intra-host viral heterogeneity, may also affect outcomes but are not fully considered in RSV&#xD;
      infection. Exploring the impact of these factors is difficult due to the heterogeneity of the&#xD;
      population which makes statistical adjustment difficult. Thus, twin models are useful in&#xD;
      understanding the impact of the host on the environment, as twins often share similar&#xD;
      exposure to infection and many risk factors, but not all are ie different prenatal and&#xD;
      postnatal conditions, differential transfer of maternal antibodies and the genetic makeup of&#xD;
      heterozygotes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of discordant twin pairs in severity of RSV-infections.</measure>
    <time_frame>1 day</time_frame>
    <description>The primary outcome measure is the percentage of discordant twin pairs of at least one severity level on the WHO (World Health Organization) scale.&#xD;
The discrepancy in the level of severity is obtained by retrospective analysis of the data from the medical file.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>RSV Infection</condition>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>Twins</arm_group_label>
    <description>Twins identified from the birth cohort (Hospices Civils de Lyon) with at least one twin hospitalized for an acute RSV-infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epidemiology</intervention_name>
    <description>Assessment of the discrepancy of clinical severity of RSV-infections between twin infants.</description>
    <arm_group_label>Twins</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Twins identified from the birth cohort (Hospices Civils de Lyon) with at least one twin&#xD;
        hospitalized for an acute RSV-infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Twins born at Hospices Civils de Lyon in the years 2012 to 2020&#xD;
&#xD;
          -  At least one twin hospitalized with positive RSV-PCR during the first year of life&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major differential underlying disease between twins&#xD;
&#xD;
          -  Death of a twin before the RSV epidemic period of the first year of life&#xD;
&#xD;
          -  Nosocomial infection&#xD;
&#xD;
          -  Lack of understanding of the study or questionnaire by parents&#xD;
&#xD;
          -  Lack of parental consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>354 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique PLOIN, Dr</last_name>
    <phone>04 27 85 56 42</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.ploin@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Sébastien CASALEGNO, MCU-PH</last_name>
    <phone>04 72 07 10 23</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-sebastien.casalegno@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant des Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique PLOIN, Dr</last_name>
      <phone>04 27 85 56 42</phone>
      <phone_ext>+33</phone_ext>
      <email>dominique.ploin@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mona MASSOUD, Dr</last_name>
      <phone>04 27 85 65 65</phone>
      <phone_ext>+33</phone_ext>
      <email>mona.massoud@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel RAULT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV infections in twins</keyword>
  <keyword>Bronchiolitis</keyword>
  <keyword>very-severe-LRTI</keyword>
  <keyword>severe-LRTI</keyword>
  <keyword>LRTI</keyword>
  <keyword>upper respiratory tract infection</keyword>
  <keyword>RSV infection</keyword>
  <keyword>Human</keyword>
  <keyword>infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

